Multicenter Comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A Reference Method for Testing Clinical Isolates of Common and Emerging Candidaspp., Cryptococcus spp., and Other Yeasts and Yeast-Like Organisms

DOI: 10.1128/JCM.37.3.591-595.1999

Article Figures & Data

Table 1.

Percent agreement between colorimetric and NCCLS reference broth microdilution MIC pairs^a

Fungus (no. of isolates tested)	Antifungal agent	% Agreement (range) between MIC pairs at incubation time (h)
Fungus (no. of isolates tested)	Antifungal agent	24 vs 24	48 vs 48	24 vs 48
C. albicans (465)	Amphotericin B	97	97	76
	Fluconazole	87	60	71
	Flucytosine	87	56	89
	Itraconazole	89	54	76
	Ketoconazole	90	56	69
Other commonCandida spp. (417)^b	Amphotericin B	85–97	92–99	40–75
	Fluconazole	95–98	73–99	91–99
	Flucytosine	92–99	73–100	89–97
	Itraconazole	93–100	66–97	86–97
	Ketoconazole	93–100	66–97	85–97
Emerging Candida spp. (64)^c	Amphotericin B	90	90	63
	Fluconazole	98	94	97
	Flucytosine	95	99	77
	Itraconazole	92	91	90
	Ketoconazole	95	94	85
C. neoformans (107)^d	Amphotericin B	ND	76	ND
	Fluconazole	ND	98	ND
	Flucytosine	ND	96	ND
	Itraconazole	ND	96	ND
	Ketoconazole	ND	90	ND
Miscellaneous yeasts and yeast-like organisms (68)^e	Amphotericin B	91	99	67
	Fluconazole	100	99	99
	Flucytosine	99	99	94
	Itraconazole	97	95	90
	Ketoconazole	94	97	90

↵a Sensititre YeastOne Colorimetric Antifungal Panel MICs versus NCCLS broth microdilution M27-A MICs. An incubation time of 48 to 96 h was used for C. neoformans and certain emerging yeast pathogens. ND, not determined.
↵b Species included 77 to 95 isolates each ofC. glabrata, C. krusei, C. lusitaniae,C. parapsilosis, and C. tropicalis.
↵c Species included 5 to 26 isolates each ofC. ciferrii, C. famata, C. guilliermondii, C. kefyr, C. lambica,C. lypolytica, C. rugosa, and C. zeylanoides.
↵d The eight non-C. neoformans Cryptococcus isolates tested are not listed.
↵e Species included 2 to 23 isolates each ofB. capitatus, H. anomala, R. rubra,R. minuta, S. cerevisiae, S. salmonicolor, and T. beigelii.

Table 2.

Percent agreement between YeastOne panel and NCCLS reference method for ranking isolates of common Candidaspp. within the established breakpoints^a

Antifungal agent	Category and breakpoint (μg/ml)^b	% Agreement by species (no. of isolates at each breakpoint)
Antifungal agent	Category and breakpoint (μg/ml)^b	C. albicans	C. glabrata	C. krusei	C. lusitaniae	C. parapsilosis	C. tropicalis
Fluconazole	S (≤8)	89 (442)	96 (49)	NA^c	96 (76)	98 (87)	95 (89)
	S-DD (16–32)	75 (12)	94 (32)	NA	ND (0)	ND (7)	ND (2)
	R (≥64)	93 (14)	100 (14)	NA	ND (1)	ND (1)	ND (3)
Itraconazole	S (≤0.12)	91 (346)	ND (5)	ND (6)	93 (30)	100 (38)	100 (39)
	S-DD (0.2–0.5)	24 (104)	97 (40)	100 (49)	98 (43)	100 (54)	89 (48)
	R (≥1.0)	50 (18)	90 (48)	100 (12)	ND (4)	ND (3)	ND (7)
Flucytosine	S (≤4)	88 (446)	98 (93)	91 (23)	98 (64)	99 (95)	95 (88)
	I (8–16)	ND (2)	ND (0)	100 (44)	ND (1)	ND (0)	ND (2)
	R (≥32)	75 (20)	ND (2)	ND (0)	100 (12)	ND (0)	ND (4)

↵a MICs were read at 24 h for both methods. ND, not determined.
↵b NCCLS breakpoints: S, susceptible; S-DD, susceptible-dose dependent; I, intermediate; R, resistant.
↵c NA, not applicable: the breakpoints do not apply to C. krusei and fluconazole (intrinsically resistant species).